Game Plan: Strategies for Achieving the Best Visual Outcomes -

Please click "Next Page" below to proceed to the posttest & evaluation to obtain your credit.

Thank you for attending. The posttest for credit will not be available immediately.

It will be accessible once the link has been emailed to you, which will be within 48 hours of the conclusion of the symposium.

Note for ODs: COPE guidelines dictate that in order to receive credit, learners must remain present at the synchronous virtual activity until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.

Scroll back to top

Details

Overview
Allen C. Ho, MD, FACS, FASRS; Michael A. Klufas, MD; and Christina Y. Weng MD, MBA, come together to deliberate on the latest approaches for managing diabetic eye disease and will examine strategies to improve patient compliance and minimize loss to follow-up. These well-known retina specialists will share their insight and expertise on disease management, including the optimal time for referral to a retina specialist for treatment, as well as the latest data on longer duration therapies.
Note About Obtaining Credit: You must remain logged in to the synchronous virtual symposium until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.
The posttest will not be available immediately. It will be accessible once the link has been emailed to you, which will be within 48 hours of the conclusion of the symposium.
To receive credit, you must complete the posttest and evaluation and proceed to the claim credit page. Only attendees are eligible for credit.

This activity is supported by an unrestricted educational grant from Regeneron Pharmaceuticals, Inc.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Develop an understanding of timely referrals to provide optimal outcomes as well as the reasons associated with loss to follow-up and execute strategies to improve patient compliance with treatment
- Interpret clinical data supporting the treatment of patients with moderate nonproliferative diabetic retinopathy (DR) without macular edema with anti-VEGF therapy
- Discuss longer duration therapies for DR and diabetic macular edema
Accreditation
Evolve Medical Education, LLC is a COPE-accredited administrator.
This activity, COPE Activity Number 126547, is accredited by COPE for continuing education for optometrists. This course is approved for 1.5 hour of CE.
Course #: 85902-TD
Activity #: 126547
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Participation Method
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Faculty and Disclosures
Allen C. Ho, MD, FACS
Director, Retina Research
Wills Eye Hospital
Philadelphia, PA

Michael A. Klufas, MD
Retina Service, Wills Eye Hospital
Associate Professor of Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA

Christina Y. Weng, MD, MBA
Professor of Ophthalmology
Fellowship Program Director-Vitreoretinal Diseases & Surgery
Baylor College of Medicine
Houston, TX

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Allen C. Ho, MD, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AcuSurgical, Adverum Biotechnologies, Aerie Pharmaceuticals, AGTC, Alcon, Aldeyra, Allergan, Apellis Pharmaceuticals, AsclepiX Therapeutics, Astellas, Atsena Therapeutics, Beaver-Visitec International, Clearside Biomedical, Dompé, Exegenesis Bio, EyePoint Pharmaceuticals, Eyevensys, Genentech, Gyroscope Therapeutics, Iveric Bio, Janssen/Johnson & Johnson Vision, Kiora Pharmaceuticals, Lineage, Nanoscope Therapeutics, Neurotech Pharmaceuticals, Notal, Novartis, Ocugen, Ocular Therapeutix, ONL Therapeutics, Orasis Pharmaceuticals, Oxular, Regeneron, Regenxbio/AbbVie, and Stealth. Speaker’s Bureau: Adverum Biotechnologies, Aerie Pharmaceuticals, AGTC, Alcon, Aldeyra, Allergan, Apellis Pharmaceuticals, AsclepiX Therapeutics, Atsena Therapeutics, Genentech, Gyroscope Therapeutics, Iveric Bio, Janssen/Johnson & Johnson Vision, Lineage, Lumithera, National Eye Institute, Notal, Novartis, ProQR, Regeneron, and Regenxbio/AbbVie. Grant/Research Support: Covalent Medical, Gyroscope Therapeutics, Kiora Pharmaceuticals, and ONL Therapeutics.
Michael A. Klufas, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Allergan, Bausch + Lomb, and Regenxbio. Grant/Research Support: Bausch + Lomb. Speaker's Bureau: Biogen, Coherus Biosciences, Genentech, and Regeneron.
Christina Y. Weng, MD, MBA, has had a financial relationship or affilaiation with the following ineligible companies in the form of Consultant: Alcon, Alimera Sciences, Allergan/AbbVie, Apellis Pharmaceuticals, DORC, EyePoint Pharmaceuticals, Genentech, Iveric Bio, Novartis, Regeneron, and Regenxbio. Grant/Research Support: AGTC, Alimera Sciences, and DRCR Retina Network. Royalties: Springer Publishers.
The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron Pharmaceuticals, Inc.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Note About Obtaining Credit: You must remain logged in to the synchronous virtual symposium until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.

The posttest will not be available immediately. It will be accessible once the link has been emailed to you, which will be within 48 hours of the conclusion of the symposium.
To receive credit, you must complete the posttest and evaluation and proceed to the claim credit page. Only attendees are eligible for credit.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 09/29/2023

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Title

Share on ReachMD